Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Lenvatinib for Advanced Uterine and Ovarian Carcinosarcomas
NCT05147558Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2021
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and lenvatinib in uterine carcinosarcoma (UCS) and ovarian carcinosarcoma (OCS), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Overall Response Rate at 1 year and Progression-Free Survival at 27 weeks. Started Dec 2021; status: active, not recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
uterine carcinosarcoma (UCS)ovarian carcinosarcoma (OCS)
Beyond the preview
Go deeper on NCT05147558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147558.